Prognostic significance of CD30 expression in diffuse large b-cell lymphoma: a systematic review with meta-analysis

Página do item simplificado
dc.creatorCarla Isabelly Rodrigues- Fernandes
dc.creatorPablo Agustin Vargas
dc.creatorLucas Guimarães Abreu
dc.creatorRaghu Radhakrishnan
dc.creatorDanyel Elias da Cruz Perez
dc.creatorGleyson Kleber Amaral- Silva
dc.creatorRogério de Oliveira Gondak
dc.creatorSiavash Rahimi
dc.creatorPeter Brennan
dc.creatorFelipe Paiva Fonseca
dc.date.accessioned2023-11-23T18:46:00Z
dc.date.accessioned2025-09-08T22:50:21Z
dc.date.available2023-11-23T18:46:00Z
dc.date.issued2021
dc.identifier.doihttps://doi.org/10.1111/jop.13208
dc.identifier.issn09042512
dc.identifier.urihttps://hdl.handle.net/1843/61315
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofJournal of Oral Pathology & Medicine
dc.rightsAcesso Restrito
dc.subjectBrentuximab vedotin
dc.subjectKi-1 Antigen
dc.subjectLymphoma, B-Cell
dc.subjectLymphoma
dc.subjectPrognosis
dc.subjectSurvival rate
dc.subjectProteins
dc.subjectSystematic review
dc.subject.otherLinfoma
dc.subject.othernome periódico Journal of oral pathology & medicineacesso restrito nome periódico Journal of oral pathology & medicine Prognostic significance of cd30 expression in diffuse large b-cell lymphoma: a systematic review with meta-analysis fao clinica e fao odontopediatria assunto Brentuximab Vedotin busca dia 07 do 11 novembro ano 2023
dc.titlePrognostic significance of CD30 expression in diffuse large b-cell lymphoma: a systematic review with meta-analysis
dc.typeArtigo de periódico
local.citation.epage593
local.citation.issue6
local.citation.spage587
local.citation.volume50
local.description.resumoBackground: CD30 is variably expressed in diffuse large B-cell lymphoma (DLBCL), but its prognostic potential for the affected patients remains debatable and unclear. Therefore, we aimed to determine the frequency of CD30 expression in DLBCL and its potential for prognostic determination. Methods: An electronic systematic review was performed using multiple databases, followed by a quantitative meta-analysis to assess the frequency of CD30 expression with positivity cut-off values of >0% and >20%, and to determine its association with clinicopathological features and patients' survival. Results: Using a cut-off value >0%, we observed that 3.5%-59.1% of the cases were considered positive for CD30. There was a significant association of the protein expression with a lower number of extra-nodal sites affected by the neoplasm, with Ann Arbor advanced stage, the absence of B-symptoms, the lack of MYC and BCL2 translocations, and a lower ECOG performance. Using a cut-off value >20%, we observed that 2.5%-36.7% of the cases were considered positive for CD30, being significantly associated with a lower number of extra-nodal sites affected by the neoplasm, Ann Arbor stages III/IV, non-GCB tumours, the lack of MYC and BCL2 translocations, and a lower ECOG value. CD30 expression was significantly associated with a better survival rate, regardless of what cut-off parameter was used. Conclusion: Despite variations in the cut-off values used to determine CD30 positivity in DLBCL, the expression of this protein seems to be associated with a higher survival rate and better prognosis.
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICA
local.publisher.departmentFAO - DEPARTAMENTO DE ODONTOPEDIATRIA E ORTODONTIA
local.publisher.initialsUFMG
local.url.externahttps://onlinelibrary.wiley.com/doi/10.1111/jop.13208

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
978 B
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG